• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 152
  • 47
  • 37
  • 11
  • 9
  • 5
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • Tagged with
  • 362
  • 190
  • 168
  • 44
  • 43
  • 43
  • 37
  • 37
  • 36
  • 36
  • 35
  • 33
  • 30
  • 30
  • 28
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
331

Treinamento resistido e locomoção de idosos saudáveis e pacientes com doença de Parkinson : explorando as variáveis específicas que beneficiam o desempenho da locomoção /

Rojas Jaimes, Diego Alejandro January 2019 (has links)
Orientador: Lilian Teresa Bucken Gobbi / Resumo: O treinamento resistido tem sido estudado no contexto do envelhecimento e da doença de Parkinson, mas há falta de exploração das características deste tipo de treinamento que contribuem na melhora da locomoção e da funcionalidade. A pergunta central desta tese é: Quais características do treinamento resistido no contexto do envelhecimento saudável e da doença de Parkinson permitem potenciar seus efeitos no desempenho locomotor? Para responder este questionamento foram desenvolvidos dois estudos. ESTUDO 1. Novos modelos de periodização do treinamento, como a periodização ondulatória e a periodização inversa, têm sido desenvolvidos, mas não há evidências sobre as vantagens da periodização ondulatória quando comparada com a periodização linear em idosos. Por outro lado, a periodização inversa não tem sido testada em idosos. Assim, o objetivo do presente estudo foi analisar os efeitos de dois treinamentos de força com periodizações diferentes na locomoção de idosos saudáveis. Participaram 69 idosos (70,23±6,81 anos, 72,58±5,51 Kg, 162,26±5,92 cm), cognitivamente preservados (27,40±1,20 pontos Mini-Exame de Estado Mental) e fisicamente ativos (12,64±3,15 pontos Baecke). A amostra foi distribuída em três grupos, grupo de treinamento de força com periodização inversa ondulatória (GPIO n=25), grupo de treinamento de força com periodização linear (GPL n=25) e grupo controle (GC n=19). Foram realizadas 20 semanas de treinamento resistido, 2 dias na semana, mais 1 dia de treinamento loc... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Resistance training has been studied in the context of aging and Parkinson's disease, but there is a lack of exploration of the characteristics of this type of training that contribute to the improvement of locomotion and functionality. The central question of this thesis is: What characteristics of resistance training in the context of healthy aging and Parkinson's disease allow to enhance its effects on locomotor performance? To answer this question two studies were developed. STUDY 1. New models of training periodization, such as undulating periodization and inverse periodization, have been developed, but there is no evidence about the advantages of wave periodization compared to linear periodization in the elderly. On the other hand, inverse periodization has not been tested in the elderly. Thus, the aim of the present study was to analyze the effects of two strength training with different periodizations on the mobility of healthy elderly. Participants were 69 elderly (70.23 ± 6.81 years, 72.58 ± 5.51 Kg, 162.26 ± 5.92 cm), cognitively preserved (27.40 ± 1.20 points Mini Mental State Examination) and physically active (12.64 ± 3.15 Baecke points). The sample was divided into three groups, strength training group with inverse undulating periodization (IUPG n = 25), force training group with linear periodization (LPG n = 25) and control group (CG n = 19). We performed 20 weeks of resistance training, 2 days a week, plus 1 day of locomotor training. GPIO performed a decreas... (Complete abstract click electronic access below) / Doutor
332

Novel nanoparticle-based drug delivery system for neural stem cell targeting and differentiation / Nouveau système de délivrance de médicament à base de nanoparticules pour le ciblage et la différenciation de cellules souches neurales

Carradori, Dario 21 September 2017 (has links)
Les cellules souches neurales (CSNs) se situent dans des régions spécifiques du système nerveux central qui sont appelées niches. Ces cellules sont capables de se répliquer ou se différentier en cellules neurales spécialisées (neurones, astrocytes et oligodendrocytes). C’est grâce à cette propriété de différentiation que les CSNs sont étudiées comme thérapie chez les patients atteints d’une maladie neurodégénérative. En effet, elles pourraient remplacer les cellules neurales altérées et ainsi restaurer les fonctions neurologiques. De nombreuses approches ont été développées afin de stimuler la différentiation des CSNs, dont la plus prometteuse est la différentiation des cellules endogènes directement au sein de leurs niches. Actuellement, il n’existe pas de molécule active ou de système thérapeutique qui cible les CSNs endogènes et qui induit leur différentiation simultanément. Le but de ce travail est de fournir un système de délivrance de molécules bioactives capable de cibler les CSNs endogènes et d'induire leur différenciation in situ. Nous avons développé et caractérisé des nanoparticules lipidiques (LNC), un système de délivrance très versatile. NFL-TBS.40-63, un peptide ciblant les CSNs, a été adsorbé à la surface des LNC afin de les diriger contre les CSNs endogènes. Nous avons observé que ces NFL-LNC ne ciblaient que les CSNs du cerveau et pas de la moelle. Afin d’étudier les interactions spécifiques entre les nanoparticules et les CSNs, nous avons caractérisé et comparé les propriétés de leur membrane plasmique. Enfin, nous avons encapsulé de l’acide rétinoïque, une molécule connue pour stimuler la différentiation des CSNs, dans les LNC-NFL et étudié leur impact sur la différentiation de CSNs in vitro et in vivo. Ce travail contribue au développement de thérapies efficaces et sures pour le traitement de maladies neurodégénératives à travers la différentiation de CSNs endogènes. / Neural stem cells (NSCs) are located in specific regions of the central nervous system called niches. Those cells are able to self-renew and to differentiate into specialized neuronal cells (neurons, astrocytes and oligodendrocytes). Due to this differentiation property, NSCs are studied to replace neuronal cells and restore neurological functions in patients affected by neurodegenerative diseases. Several therapeutic approaches have been developed and endogenous NSC stimulation is one of the most promising. Currently, there is no active molecule or therapeutic system targeting endogenous CSNs and inducing their differentiation at the same time. The aim of the work was to provide a drug delivery system able both to target endogenous CSNs and to induce their differentiation in situ. Here, we developed and characterized lipidic nanoparticles (LNC) targeting endogenous NSCs. A peptide called NFL-TBS.40-63, known for its affinity towards NSCs, was adsorbed at the surface of LNC. We observed that NFL-LNC specifically targeted NSC from the brain and not from the spinal cord in vitro and in vivo. To explain this specificity, we characterized and compared NFL-LNC interactions with the plasmatic membrane of both cell types. Finally, we demonstrated that by loading retinoic acid in NFL-LNC we were able to induce brain NSC differentiation in vitro and in vivo. This work contributes to the development of efficient and safe therapies for the treatment of neurodegenerative disease via the differentiation of endogenous NSCs.
333

Visual Transformers for 3D Medical Images Classification: Use-Case Neurodegenerative Disorders

Khorramyar, Pooriya January 2022 (has links)
A Neurodegenerative Disease (ND) is progressive damage to brain neurons, which the human body cannot repair or replace. The well-known examples of such conditions are Dementia and Alzheimer’s Disease (AD), which affect millions of lives each year. Although conducting numerous researches, there are no effective treatments for the mentioned diseases today. However, early diagnosis is crucial in disease management. Diagnosing NDs is challenging for neurologists and requires years of training and experience. So, there has been a trend to harness the power of deep learning, including state-of-the-art Convolutional Neural Network (CNN), to assist doctors in diagnosing such conditions using brain scans. The CNN models lead to promising results comparable to experienced neurologists in their diagnosis. But, the advent of transformers in the Natural Language Processing (NLP) domain and their outstanding performance persuaded Computer Vision (CV) researchers to adapt them to solve various CV tasks in multiple areas, including the medical field. This research aims to develop Vision Transformer (ViT) models using Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset to classify NDs. More specifically, the models can classify three categories (Cognitively Normal (CN), Mild Cognitive Impairment (MCI), Alzheimer’s Disease (AD)) using brain Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) scans. Also, we take advantage of Automated Anatomical Labeling (AAL) brain atlas and attention maps to develop explainable models. We propose three ViTs, the best of which obtains an accuracy of 82% on the test dataset with the help of transfer learning. Also, we encode the AAL brain atlas information into the best performing ViT, so the model outputs the predicted label, the most critical region in its prediction, and overlaid attention map on the input scan with the crucial areas highlighted. Furthermore, we develop two CNN models with 2D and 3D convolutional kernels as baselines to classify NDs, which achieve accuracy of 77% and 73%, respectively, on the test dataset. We also conduct a study to find out the importance of brain regions and their combinations in classifying NDs using ViTs and the AAL brain atlas. / <p>This thesis was awarded a prize of 50,000 SEK by Getinge Sterilization for projects within Health Innovation.</p>
334

Neurotoxins and Neurotoxicity Mechanisms. An Overview

Segura-Aguilar, Juan, Kostrzewa, Richard M. 01 December 2006 (has links)
Neurotoxlns represent unique chemical tools, providing a means to 1) gain insight into cellular mechanisms of apopotosis and necrosis, 2) achieve a morphological template for studies otherwise unattainable, 3) specifically produce a singular phenotype of denervation, and 4) provide the starting point to delve into processes and mechanisms of nerve regeneration and sprouting. There are many other notable uses of neurotoxins in neuroscience research, and ever more being discovered each year. The objective of this review paper is to highlight the broad areas of neuroscience in which neurotoxins and neurotoxicity mechanism come into play. This shifts the focus away from neurotoxins per se, and onto the major problems under study today. Neurotoxins broadly defined are used to explore neurodegenerative disorders, psychiatric disorders and substance use disorders. Neurotoxic mechanisms relating to protein aggregates are indigenous to Alzheimer disease, Parkinson's disease. NeuroAIDS is a disorder in which microglia and macrophages have enormous import. The gap between the immune system and nervous system has been bridged, as neuroinflammation is now considered to be part of the neurodegenerative process. Related mechanisms now arise in the process of neurogenesis. Accordingly, the entire spectrum of neuroscience is within the purview of neurotoxins and neurotoxicity mechanisms. Highlights on discoveries in the areas noted, and on selective neurotoxins, are included, mainly from the past 2 to 3 years.
335

A CNS-Active siRNA Chemical Scaffold for the Treatment of Neurodegenerative Diseases

Alterman, Julia F. 13 May 2019 (has links)
Small interfering RNAs (siRNAs) are a promising class of drugs for treating genetically-defined diseases. Therapeutic siRNAs enable specific modulation of gene expression, but require chemical architecture that facilitates efficient in vivodelivery. siRNAs are informational drugs, therefore specificity for a target gene is defined by nucleotide sequence. Thus, developing a chemical scaffold that efficiently delivers siRNA to a particular tissue provides an opportunity to target any disease-associated gene in that tissue. The goal of this project was to develop a chemical scaffold that supports efficient siRNA delivery to the brain for the treatment of neurodegenerative diseases, specifically Huntington’s disease (HD). HD is an autosomal dominant neurodegenerative disorder that affects 3 out of every 100,000 people worldwide. This disorder is caused by an expansion of CAG repeats in the huntingtin gene that results in significant atrophy in the striatum and cortex of the brain. Silencing of the huntingtin gene is considered a viable treatment option for HD. This project: 1) identified a hyper-functional sequence for siRNA targeting the huntingtin gene, 2) developed a fully chemically modified architecture for the siRNA sequence, and 3) identified a new structure for siRNA central nervous system (CNS) delivery—Divalent-siRNA (Di-siRNA). Di-siRNAs, which are composed of two fully chemically-stabilized, phosphorothioate-containing siRNAs connected by a linker, support potent and sustained gene modulation in the CNS of mice and non-human primates. In mice, Di-siRNAs induced potent silencing of huntingtin mRNA and protein throughout the brain one month after a single intracerebroventricular injection. Silencing persisted for at least six months, with the degree of gene silencing correlating to guide strand tissue accumulation levels. In Cynomolgus macaques, a bolus injection exhibited significant distribution and robust silencing throughout the brain and spinal cord without detectable toxicity. This new siRNA scaffold opens the CNS for RNAi-based gene modulation, creating a path towards developing treatments for genetically-defined neurological disorders.
336

Study of Hsp70/CHIP mediated Protein Quality Control by Folding Sensors

Karunanayake, Chamithi Samadharshi 21 June 2023 (has links)
No description available.
337

Analytical Approaches to Neurodegenerative Disease Protein Aggregation

Wiberg, Henning January 2011 (has links)
<p>QC 20110615</p>
338

Inflammation-Dependent Oxidative Stress Metabolites as a Hallmark of Amyotrophic Lateral Sclerosis

Xiong, Luyang, McCoy, Michael, Komuro, Hitoshi, West, Xiaoxia Z., Yakubenko, Valentin, Gao, Detao, Dudiki, Tejasvi, Milo, Amanda, Chen, Jacqueline, Podrez, Eugene A., Trapp, Bruce, Byzova, Tatiana V. 01 January 2022 (has links)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease, with poor prognosis and no cure. Substantial evidence implicates inflammation and associated oxidative stress as a potential mechanism for ALS, especially in patients carrying the SOD1 mutation and, therefore, lacking anti-oxidant defense. The brain is particularly vulnerable to oxidation due to the abundance of polyunsaturated fatty acids, such as docosahexaenoic acid (DHA), which can give rise to several oxidized metabolites. Accumulation of a DHA peroxidation product, CarboxyEthylPyrrole (CEP) is dependent on activated inflammatory cells and myeloperoxidase (MPO), and thus marks areas of inflammation-associated oxidative stress. At the same time, generation of an alternative inactive DHA peroxidation product, ethylpyrrole, does not require cell activation and MPO activity. While absent in normal brain tissues, CEP is accumulated in the central nervous system (CNS) of ALS patients, reaching particularly high levels in individuals carrying a SOD1 mutation. ALS brains are characterized by high levels of MPO and lowered anti-oxidant activity (due to the SOD1 mutation), thereby aiding CEP generation and accumulation. Due to DHA oxidation within the membranes, CEP marks cells with the highest oxidative damage. In all ALS cases CEP is present in nearly all astrocytes and microglia, however, only in individuals carrying a SOD1 mutation CEP marks >90% of neurons, thereby emphasizing an importance of CEP accumulation as a potential hallmark of oxidative damage in neurodegenerative diseases.
339

Studies on Bioactive Lipid Mediators Involved in Brain Function and Neurodegenerative Disorders. The effect of ¿-3PUFA supplementation and lithium treatment on rat brain sphingomyelin species and endocannabinoids formation; changes in oxysterol profiles in blood of ALS patients and animal models of ALS.

Drbal, Abed Alnaser A.A. January 2013 (has links)
Lipids are important for structural and physiological functions of neuronal cell membranes. They exhibit a range of biological effects many are bioactive lipid mediators derived from polyunsaturated fatty acids such as sphingolipids, fatty acid ethanolamides (FA-EA) and endocannabinoids (EC). These lipid mediators and oxysterols elicit potent bioactive functions in many physiological and pathological processes of the brain and neuronal tissues. They have been investigated for biomarker discovery of ageing, neuroinflammation and neurodegenerative disorders. The n-3 fatty acids EPA and DPA are thought to exhibit a range of neuroprotective effects many of which are mediated through production of such lipid mediators. The aims of this study were to evaluate the effects of n-3 EPA and n-3 DPA supplementation on RBC membranes and in this way assess dietary compliance and to investigate brain sphingomyelin species of adult and aged rats supplemented with n-3 EPA and n-3 DPA to evaluate the effects and benefits on age-related changes in the brain. Furthermore, to study the effects of lithium on the brain FA-EAs and ECs to further understand the neuroprotective effects of lithium neuroprotective action on neuroinflammation as induced by LPS. Finally to examine if circulating oxysterols are linked to the prevalence of ALS and whether RBC fatty acids are markers of this action in relation to age and disease stages. These analytes were extracted from tissue samples and analysed with GC, LC/ESI-MS/MS and GC-MS. It was found that aged rats exhibited a significant increase in brain AA and decrease in ¿n-3 and ¿n-6 PUFAs when compared to adult animals. The observed increase of brain AA was reversed following n-3 EPA and n-3 DPA supplementation. Sphingomyelin was significantly increased when aged animals were supplemented with n-3 DPA. LPS treatment following lithium supplementation increased LA-EA and ALA-EA, while it decreased DHA-EA. Both oxysterols 24-OH and 27-OH increased in ALS patients and SOD1-mice. Eicosadienoic acid was different in ASL-patients compared to aged SOD1-mice. These studies demonstrated that dietary intake of n-3 EPA and n-3DPA significantly altered RBC fatty acids and sphingolipids in rat brain. They suggest that n-3 DPA can be a potential storage form for EPA, as shown by retro-conversion of n-3 DPA into EPA in erythrocyte membranes, ensuring supply of n-3 EPA. Also, n-3 EPA and n-3 DPA supplementation can contribute to an increase in brain sphingomyelin species with implications for age effects and regulation of brain development. Effects of lithium highlight novel anti-neuroinflammatory treatment pathways. Both 24-hydroxycholesterol and eicosadienoic acid may be used as biomarkers in ALS thereby possibly helping to manage the progressive stages of disease. / Libyan Government
340

Hippocampal Neurogenesis In Amyotrophic Lateral Sclerosis Like Mice

Ma, Xiaoxing 10 1900 (has links)
<p> G93A SODI mice (G93A mice) are a transgenic model over-expressing a mutant human Cu/Zn-SOD gene, and are a model for amyotrophic lateral sclerosis (ALS), a predominantly motor neurodegenerative disease. Hippocampal neurogenesis in the subgranular zone (SGZ) of dentate gyms (DG) occurs throughout the life. It is regulated by many pathological and physiological processes. There is controversy with respect to the basal level of hippocampal neurogenesis and its response to exercise in neurodegenerative diseases and their mouse models. Little information regarding hippocampal neurogenesis is available in G93A mice. The present study was designed to study the impact of treadmill exercise and sex differences on hippocampal neurogenesis in this model. In addition, potential molecular mechanisms regulating hippocampal neurogenesis including growth factors (BDNF and IGFl) and oxidative stress (SOD2, catalase, 8-0Hdg, and 3-NT) were also addressed in the study. Bromodeoxyuridine (BrdU) was used to label newly generated cells. G93A and wild type (WT) mice were subjected to treadmill exercise (EX) or a sedentary (SEO) lifestyle. Immunohistochemistry was used to detect BrdU labeled newly proliferating cells, surviving cells, and their phenotype, as well as for determination of oxidative stress. BDNF and IGFl mRNA expression was assessed by in situ hybridization. Results showed that (1) G93A mice had an elevated basal level of hippocampal neurogenesis for both cell survival and neuronal differentiation, a growth factor (BDNF mRNA), and an oxidative stress marker (NT), as compared to wild type sedentary mice. (2) Treadmill running did not show any further effect on hippocampal neurogenesis, growth factors, oxidative stress, and antioxidant enzymes in G93A mice, while treadmill running promoted hippocampal neurogenes1s and expression of the growth factor (BDNF mRNA), and lowered oxidative stress (8-0Hdg) in WT mice. (3) There also were sex differences in hippocampal neurogenesis in G93A mice, whereby male G93A mice had a significant higher level of cell proliferation but a lower level of survival than female G93A mice. (4) The DG BDNF mRNA was associated with cell survival and neuronal differentiation in sedentary G93A mice, suggesting that BDNF is associated with a higher basal level of hippocampal neurogenesis in G93A mice. We conclude that G93A mice are more permissive in the context of hippocampal neurogenesis, which is associated with elevated DG BDNF mRNA expression. Running did not have impact on hippocampal neurogenesis and BDNF mRNA expression in G93A mice, probably due to a 'ceiling effect' of the already heightened basal levels of hippocampal neurogenesis and BDNF mRNA in this model. In addition, sex differences also affect hippocampal neurogenes1s, but the further study is needed to clarify the underlying molecular mechanisms. </p> / Thesis / Doctor of Philosophy (PhD)

Page generated in 0.2079 seconds